Evidence map›Paper›PMID 25285812›Full record

SynthesisJAMA neurology2014

Amyotrophic lateral sclerosis risk for spinocerebellar ataxia type 2 ATXN2 CAG repeat alleles: a meta-analysis.

Annalese G Neuenschwander, Khanh K Thai, Karla P Figueroa, Stefan M Pulst

Erratum issuedAbstract readMeta-Analysis
In one paragraph

Synthesis in JAMA neurology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 48 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
48citing papers in PubMed, 1 pooled it
4.1field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

48 citing papers in PubMed, 1 synthesis or guideline pooled it, 73 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Expanding the Genetic Landscape ofNeurology. Genetics · 2026
    Article
  5. Review
  6. Observational
  7. Article
  8. Review
  9. Article
  10. Rare association between spinocerebellar ataxia and amyotrophic lateral sclerosis: a case series.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2024
    Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Review
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

  • Erratum issued
5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Annalese G NeuenschwanderDepartment of Neurology, University of Utah, Salt Lake City.
Khanh K ThaiDepartment of Neurology, University of Utah, Salt Lake City.
Karla P FigueroaDepartment of Neurology, University of Utah, Salt Lake City.
Stefan M PulstDepartment of Neurology, University of Utah, Salt Lake City.
University of Utah · US

Funding

ZONA-FREE HAMSTER OVA ASSAY AS AN INDICATOR OF MALE FERTILITYM01RR000425 · NCRR · LUNDQUIST INSTITUTE FOR BIOMEDICAL INNOVATION AT HARBOR-UCLA MEDICAL CENTER · PI ANDERSON, GAIL V · 1985 to 2011
$74.2M
Spinocerebellar Ataxia Type 2 Gene and Gene ProductR37NS033123 · NINDS · UNIVERSITY OF UTAH · PI PULST, STEFAN M. · 2014 to 2020
$3.6M
SPINOCEREBELLAR ATAXIA TYPE 2--GENE AND GENE PRODUCTR01NS033123 · NINDS · UNIVERSITY OF UTAH · PI PULST, STEFAN M. · 1996 to 2012
$2.9M
Drug Discovery for Spinocerebellar Ataxia Type 2 (SCA2)RC4NS073009 · NINDS · UNIVERSITY OF UTAH · PI PULST, STEFAN M., SCOLES, DANIEL R · 2010 to 2010
$835k
Spinocerebellar Ataxia Type 2 Gene and Gene ProductR56NS033123 · NINDS · UNIVERSITY OF UTAH · PI PULST, STEFAN M. · 2013 to 2013
$473k
Identification of mutation causing Purkinje cell degeneration in the shaker ratR21NS079852 · NINDS · UNIVERSITY OF UTAH · PI PULST, STEFAN M. · 2013 to 2014
$408k
Antisense oligonucleotides for the treatment of spinocerebellar ataxia type 2R21NS081182 · NINDS · UNIVERSITY OF UTAH · PI PULST, STEFAN M., SCOLES, DANIEL R · 2013 to 2014
$408k
NCRR NIH HHS M01 RR000425NINDS NIH HHS R01 NS033123NINDS NIH HHS R01NS33123NINDS NIH HHS R21 NS079852NINDS NIH HHS R21NS079852NINDS NIH HHS R21 NS081182NINDS NIH HHS R21NS081182NINDS NIH HHS R37 NS033123NINDS NIH HHS R56 NS033123NINDS NIH HHS RC4 NS073009NINDS NIH HHS RC4NS073009
6 · The paper itself

Abstract

importanceRepeats of CAG in the ataxin 2 gene (ATXN2) in the long-normal range (sometimes referred to as intermediate) have been identified as modifiers of amyotrophic lateral sclerosis (ALS) risk. Prior studies have used thresholding considering various cutoffs for ATXN2 repeat length.

objectiveTo calculate association between ATXN2 CAG repeat alleles and increased risk of ALS across multiple ethnic groups. DATA SOURCES: The MEDLINE database was searched for studies published by December 29, 2013, reporting ATXN2 CAG repeat length in patients with ALS and controls. STUDY SELECTION: Studies were included if they reported original data on relative risks or odds ratios (ORs) from ALS and control populations for individual ATXN2 alleles. Review articles that reported no new data were not included in the analysis. DATA EXTRACTION AND SYNTHESIS: Analysis of allele distribution was performed to ensure that all studies followed identical allele sizing. The ORs, 95% confidence intervals, and population attributable risk percentages were calculated according to standard procedures. MAIN OUTCOMES AND MEASURES: Occurrence of ALS associated with ATXN2 repeat alleles, expressed as ORs.

resultsNine studies were analyzed, including 7505 controls and 6151 sporadic ALS cases. The ALS and control cohorts were recruited from different geographical and ethnic regions including the United States, French Canada/Canada, Belgium and the Netherlands, Germany, Italy, mainland China, Turkey, and Flanders-Belgium. The ATXN2 CAG repeat lengths ranged from 13 to 39 in patients with ALS and from 13 to 34 in controls. The ORs were less than 1.00 for alleles with 25 to 28 repeats. The OR was 1.55 for 30 repeats, but this elevation was not statistically significant (95% CI, 0.88-2.73). The ORs were 2.70 (95% CI, 1.47-4.93) for 31 CAG repeats, 11.09 (95% CI, 4.16-29.57) for 32 repeats, and 5.76 (95% CI, 1.79-18.57) for 33 repeats. CONCLUSIONS AND RELEVANCE: In contrast to prior studies with smaller numbers, risk for ALS associated with long-normal alleles is complex. Alleles with 27 and 28 repeats lower ALS risk slightly. The risk for ALS increases beginning with 29 repeats and reaches a maximum at 32 and 33 repeats. Of note, alleles with repeats of these lengths are known to be predisposed to meiotic expansion to full-penetrance mutant alleles. In patients with ALS, alleles with 31 to 33 repeats may have undergone preferential expansion in motor neurons during mitosis or DNA repair. Our meta-analysis provides a framework for counseling individuals with long-normal ATXN2 repeats.

Indexed as

Amyotrophic Lateral SclerosisAtaxinsHumansNerve Tissue ProteinsTrinucleotide Repeat ExpansionAtaxinsNerve Tissue Proteins

Identifiers

PMID25285812
PMCPMC4939089
OpenAlexW2109646678

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.